Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP235533.RAdGaVBtRyMctYSWIouBlN3M31rzWW2a-QrYbOENWzSg4130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP235533.RAdGaVBtRyMctYSWIouBlN3M31rzWW2a-QrYbOENWzSg4130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP235533.RAdGaVBtRyMctYSWIouBlN3M31rzWW2a-QrYbOENWzSg4130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP235533.RAdGaVBtRyMctYSWIouBlN3M31rzWW2a-QrYbOENWzSg4130_provenance.
- NP235533.RAdGaVBtRyMctYSWIouBlN3M31rzWW2a-QrYbOENWzSg4130_assertion description "[Further, unlike the benefits observed with CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma (DLBCL), peripheral T-cell lymphomas (PTCL), other than ALK-positive ALCL, are relatively chemoresistant to this regimen.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP235533.RAdGaVBtRyMctYSWIouBlN3M31rzWW2a-QrYbOENWzSg4130_provenance.
- NP235533.RAdGaVBtRyMctYSWIouBlN3M31rzWW2a-QrYbOENWzSg4130_assertion evidence source_evidence_literature NP235533.RAdGaVBtRyMctYSWIouBlN3M31rzWW2a-QrYbOENWzSg4130_provenance.
- NP235533.RAdGaVBtRyMctYSWIouBlN3M31rzWW2a-QrYbOENWzSg4130_assertion SIO_000772 19074097 NP235533.RAdGaVBtRyMctYSWIouBlN3M31rzWW2a-QrYbOENWzSg4130_provenance.
- NP235533.RAdGaVBtRyMctYSWIouBlN3M31rzWW2a-QrYbOENWzSg4130_assertion wasDerivedFrom befree-20150227 NP235533.RAdGaVBtRyMctYSWIouBlN3M31rzWW2a-QrYbOENWzSg4130_provenance.
- NP235533.RAdGaVBtRyMctYSWIouBlN3M31rzWW2a-QrYbOENWzSg4130_assertion wasGeneratedBy ECO_0000203 NP235533.RAdGaVBtRyMctYSWIouBlN3M31rzWW2a-QrYbOENWzSg4130_provenance.
- befree-20150227 importedOn "2015-02-27" NP235533.RAdGaVBtRyMctYSWIouBlN3M31rzWW2a-QrYbOENWzSg4130_provenance.